We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02604420
Recruitment Status : Completed
First Posted : November 13, 2015
Last Update Posted : March 30, 2018
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
Mortality in the major thrombotic microangiopathies (TMAs), TTP and aHUS, exceeds 90% unless rapidly diagnosed and appropriately treated. TMAs complicate 10-20% of allogeneic bone marrow hematopoietic stem cell transplants (alloHSCT), conveying inferior survival. Multiple etiologies have been proposed for these transplant-associated TMAs (TA-TMAs), but once infection, graft vs. host disease (GvHD), and drug effects have been ruled out, most are treated as TTP-like disorders using plasma exchange (PEx). But PEx has no impact on mortality in this setting. Clear definition of the pathophysiology of the TA-TMAs is required to guide effective treatment. Investigators hypothesize that an aHUS-type TMA, related to dysregulation of the alternative complement pathway, is involved and will be characterized by elevated plasma levels of C5b-9 and detectable C5b-9 deposition in bone marrow sinusoidal vessels. Investigators further hypothesize that treatment with inhibitors of terminal complement components will reverse the TMA in vivo, and block endothelial cell damage in our in vitro model systems. The data investigators generate from this observational study of TA-TMAs should enable prediction of their development prior to overt clinical manifestations, and guide appropriate therapy.

Condition or disease Intervention/treatment
Thrombotic Microangiopathy Disorder Related to Bone Marrow Transplantation Drug: eculizumab

Detailed Description:

Investigators plan to enroll 120 adult patients who are undergoing an allogeneic hematopoietic stem cell transplant and follow them serially for one year. Investigators will harvest and store at -80oC plasma and PBMCs, and collect bone marrow core biopsy specimens on all individuals at baseline, days 28, 100, 190, 365 post-transplant, and at time of relapse of primary disease relapse or TMA development. These time points, bone marrow procedures, and blood draws are part of the ordinary and customary followup of any allogeneic HSCT patient at our institution. With these patient samples investigators will:

  1. Determine the incidence of all TMAs fitting the criteria of a Coombs negative hemolytic anemia, thrombocytopenia (25% decrease from baseline) and elevated (2x baseline) LDH, with schistocytes and organ system involvement (typically increased creatinine or new microscopic hematuria or proteinuria)
  2. Determine the incidence of an aHUS-like TMA, i.e., a TMA characterized by ADAMTS13 activity in plasma >5% with clinical and laboratory findings which persists after stopping their calcineurin or mTOR inhibitor for one half life (3-7 days, depending on the drug), and ruling out or treating an underlying systemic infection or GvHD.
  3. Determine complement component activation, proinflammatory cytokine profile, and baseline complement mutations. This will include ELISA-based measures of plasma C5a, C5b-9, MASP-1-3, tumor necrosis factor(TNF)-α, and interferon-γ, and pre-transplant complement mutational analysis .
  4. Assay participants plasma for the ability to induce injury in primary human microvascular endothelial cells (MVEC), and the ability of an anti-C5 monoclonal antibody (mAb) (Alexion, eculizumab (Soliris)) and anti-MASP2 (Omeros, OMS721) mAb, to block these changes in the investigators' established model.
  5. Define the degree of C5b-9 deposition in sinusoidal CD34+ endothelial cells by immunohistochemistry, (IHC) examining marrow core biopsies collected at each patient visit and at time of TMA development.
  6. Correlate changes in plasma biomarkers, marrow sinusoidal C5b-9 deposition, and the in vitro plasma-MVEC injury model with treatment interventions and treatment outcomes, chosen by the transplant attending of record in this observational cohort.

Layout table for study information
Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of the Pathogenesis of Thrombotic Microangiopathy in the Allo Stem Cell Transplant Setting in Adults
Actual Study Start Date : September 2014
Actual Primary Completion Date : March 28, 2018
Actual Study Completion Date : March 28, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Eculizumab

Group/Cohort Intervention/treatment
Transplant, no TMA
Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
Transplant, +TMA
Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
Drug: eculizumab
Other Name: Soliris

Primary Outcome Measures :
  1. Number of participants with thrombotic microangiopathy occurring in the allogeneic stem cell transplant setting [ Time Frame: 2 years ]

    Per protocol a thrombotic microangiopathy is defined as development of:

    • increase in number of schistocytes per high power microscopic field from baseline
    • increase in baseline level of anemia, measured by hemoglobin decline, which must be Coombs negative
    • unexplained doubling from baseline of serum LDH

  2. Number of participants with allogeneic stem cell transplant-linked TMA persisting after control of infection, GvHD and altering medications [ Time Frame: 2 years ]

    Investigators will determine the number of participants with TMAs that persist after:

    • stopping calcineurin and mTOR inhibitor use for one half-life (3-7 days, depending on drug)
    • treating an underlying infection, if identified
    • suppressing new GvHD, if present

Secondary Outcome Measures :
  1. Number of participants with allogeneic stem cell transplant-linked TMA persisting after control of infection, GvHD and altering medications responsive to intervention [ Time Frame: 2 years ]
    This is an observational study. No interventions are specified, by standards of practice could include supportive care, plasma exchange, use of eculizumab (Soliris)

Biospecimen Retention:   Samples With DNA
Peripheral blood mononuclear cells Plasma Bone marrow core biopsies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults (age 18-65) undergoing an allogeneic hematopoietic stem cell transplant

Inclusion Criteria:

  • participants scheduled to undergo an allogeneic stem cell transplant
  • willing to consent to genetic testing

Exclusion Criteria:

  • pregnant women
  • nursing mothers
  • women of child-bearing potential who are unwilling to use medically accepted methods of contraception
  • patients with known contraindications to use of eculizumab
  • patients who cannot tolerate plasma exchange

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02604420

Layout table for location information
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Layout table for investigator information
Principal Investigator: Jeffrey Laurence, MD Weill Medical College of Cornell University
Publications of Results:
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT02604420    
Other Study ID Numbers: 1403014892
First Posted: November 13, 2015    Key Record Dates
Last Update Posted: March 30, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to share IPD.
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Thrombotic Microangiopathies
Cardiovascular Diseases
Blood Platelet Disorders
Hematologic Diseases
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs